Evidence-based clinical practice guidelines for irritable bowel syndrome 2020.
J Gastroenterol
; 56(3): 193-217, 2021 03.
Article
de En
| MEDLINE
| ID: mdl-33538894
Mots clés
5-HT3 antagonists; 5-HT4 agonists; Antibiotics; Antidepressant; Brain-gut interactions; Complications; Diagnosis; Epidemiology; Functional bowel disorder (FBD); Functional gastrointestinal disorders (FGIDs); Infection; Inflammation; Intestinal secretagogues (gut epithelial modifier); Irritable bowel syndrome (IBS); Microbiota; Mucosal permeability; Pathophysiology; Probiotics; Prognosis; Psychosocial stress; Psychotherapy; Rome IV criteria; Treatment
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Recommandations comme sujet
/
Syndrome du côlon irritable
Type d'étude:
Etiology_studies
/
Guideline
/
Prognostic_studies
/
Risk_factors_studies
Aspects:
Patient_preference
Limites:
Humans
Pays/Région comme sujet:
Asia
Langue:
En
Journal:
J Gastroenterol
Sujet du journal:
GASTROENTEROLOGIA
Année:
2021
Type de document:
Article
Pays d'affiliation:
Japon
Pays de publication:
Japon